OBJECTIVE: Current evidence regarding the association between psychopathology and subclinical atherosclerosis show inconsistent results. The present study examined whether subclinical atherosclerosis was more prevalent in a large cohort of persons with depressive or anxiety disorders as compared to non-depressed and non-anxious controls. METHODS: Baseline data from the Netherlands Study of Depression and Anxiety were used, including 2717 persons, free of clinical cardiovascular disease. Participants had a DSM-IV-based current or remitted depressive (major depressive disorder, dysthymia) or anxiety (social phobia, generalized anxiety disorder, panic disorder, agoraphobia) disorder (n=2115) or were healthy controls (n=602). Additional clinical characteristics (severity, duration, age of onset and medication) were assessed. Ankle-brachial index (ABI) was used as a measure of vascular risk and was categorized as low (<or=0.90) and mildly low ABI (0.90-1.11) indicating subclinical atherosclerosis, and high ABI (>1.40), which was previously designated as a cardiovascular risk factor, reflecting arterial stiffness and wall calcification. RESULTS: As compared to normal controls, persons with current (i.e., past year) depressive, anxiety or comorbid depressive and anxiety disorders showed a two- to threefold increased odds of low ABI (OR=2.78, 95% CI=1.05-7.35; OR=3.14, 95% CI=1.25-7.85; OR=2.67, 95% CI=1.09-6.51, respectively). No associations were found with mildly low or high ABI. Also, we did not further find a differential role for symptoms severity, duration, age of onset, and use of psychotropic medication in the link between psychopathology and subclinical atherosclerosis. CONCLUSION: Persons with current depressive or anxiety disorders were more likely to have subclinical atherosclerosis compared to healthy controls. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: Current evidence regarding the association between psychopathology and subclinical atherosclerosis show inconsistent results. The present study examined whether subclinical atherosclerosis was more prevalent in a large cohort of persons with depressive or anxiety disorders as compared to non-depressed and non-anxious controls. METHODS: Baseline data from the Netherlands Study of Depression and Anxiety were used, including 2717 persons, free of clinical cardiovascular disease. Participants had a DSM-IV-based current or remitted depressive (major depressive disorder, dysthymia) or anxiety (social phobia, generalized anxiety disorder, panic disorder, agoraphobia) disorder (n=2115) or were healthy controls (n=602). Additional clinical characteristics (severity, duration, age of onset and medication) were assessed. Ankle-brachial index (ABI) was used as a measure of vascular risk and was categorized as low (<or=0.90) and mildly low ABI (0.90-1.11) indicating subclinical atherosclerosis, and high ABI (>1.40), which was previously designated as a cardiovascular risk factor, reflecting arterial stiffness and wall calcification. RESULTS: As compared to normal controls, persons with current (i.e., past year) depressive, anxiety or comorbid depressive and anxiety disorders showed a two- to threefold increased odds of low ABI (OR=2.78, 95% CI=1.05-7.35; OR=3.14, 95% CI=1.25-7.85; OR=2.67, 95% CI=1.09-6.51, respectively). No associations were found with mildly low or high ABI. Also, we did not further find a differential role for symptoms severity, duration, age of onset, and use of psychotropic medication in the link between psychopathology and subclinical atherosclerosis. CONCLUSION:Persons with current depressive or anxiety disorders were more likely to have subclinical atherosclerosis compared to healthy controls. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Nicola J Paine; Lana L Watkins; James A Blumenthal; Cynthia M Kuhn; Andrew Sherwood Journal: Psychosom Med Date: 2015 Feb-Mar Impact factor: 4.312
Authors: Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer Journal: World J Biol Psychiatry Date: 2016-07-15 Impact factor: 4.132
Authors: Alex Dregan; Lauren Rayner; Katrina A S Davis; Ioannis Bakolis; Jorge Arias de la Torre; Jayati Das-Munshi; Stephani L Hatch; Robert Stewart; Matthew Hotopf Journal: JAMA Psychiatry Date: 2020-06-01 Impact factor: 21.596
Authors: Rosalba Hernandez; Norrina Bai Allen; Kiang Liu; Jeremiah Stamler; Kathryn Jean Reid; Phyllis C Zee; Donghong Wu; Joseph Kang; Daniel B Garside; Martha L Daviglus Journal: Prev Med Date: 2014-01-13 Impact factor: 4.018
Authors: Álvaro Camacho; Robyn L McClelland; Joseph A Delaney; Matthew A Allison; Bruce M Psaty; Dena E Rifkin; Stephen R Rapp; Moyses Szklo; Murray B Stein; Michael H Criqui Journal: J Clin Psychopharmacol Date: 2016-08 Impact factor: 3.153